Abstract

Erythromycin resistance methyltransferases (Erms) confer resistance to macrolide, lincosamide, and streptogramin antibiotics in Gram-positive bacteria and mycobacteria. Although structural information for ErmAM, ErmC, and ErmE exists from Gram-positive bacteria, little is known about the Erms in mycobacteria, as there are limited biochemical data and no structures available. Here, we present crystal structures of Erm38 from Mycobacterium smegmatis in apoprotein and cofactor-bound forms. Based on structural analysis and mutagenesis, we identified several catalytically critical, positively charged residues at a putative RNA-binding site. We found that mutation of any of these sites is sufficient to abolish methylation activity, whereas the corresponding RNA-binding affinity of Erm38 remains unchanged. The methylation reaction thus appears to require a precise ensemble of amino acids to accurately position the RNA substrate, such that the target nucleotide can be methylated. In addition, we computationally constructed a model of Erm38 in complex with a 32-mer RNA substrate. This model shows the RNA substrate stably bound to Erm38 by a patch of positively charged residues. Furthermore, a π-π stacking interaction between a key aromatic residue of Erm38 and a target adenine of the RNA substrate forms a critical interaction needed for methylation. Taken together, these data provide valuable insights into Erm–RNA interactions, which will aid subsequent structure-based drug design efforts.

Highlights

  • The emergence of antimicrobial resistance (AMR) in virtually every clinically important bacterial pathogen represents a true crisis with major societal and economic impact [1,2]

  • While structural information for ErmAM, ErmC, and ErmE exists from Gram-positive bacteria, little is known about the Erythromycin resistance methyltransferases (Erms) in mycobacteria, as there are limited biochemical data and no structures available

  • Transferred Erms are emerging in methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), for example, while endogenous, inducible Erms obviate the use of MLS antibiotics for Mycobacterium tuberculosis and limit their utility for Mycobacterium abscessus (6,7,9,10l,11)

Read more

Summary

INTRODUCTION

The emergence of antimicrobial resistance (AMR) in virtually every clinically important bacterial pathogen represents a true crisis with major societal and economic impact [1,2]. One major mechanism of AMR in Gram-positive and mycobacterial pathogens affects three broad classes of front-line antibiotics – macrolides, lincosamides, and streptogramins (MLS) – and is conferred by a family of horizontally- and vertically-transmitted genes that encode the socalled erythromycin resistance methyltransferases (Erms) [3,4,5,6,7]. Journal Pre-proof (SAM) as a cofactor, Erms transfer a methyl group to adenosine at position 2058 (A2058) in the ~3000 nucleotide-long 23S ribosomal RNA. This subtle post-transcriptional modification blocks the antibiotic binding site in the ribosomal peptide exit tunnel [8]. Mutagenesis data and computational tools enabled us to build an atomic model for the Erm38RNA complex, which will aid future drug discovery efforts

RESULTS
DISCUSSION
FUNDING AND ADDITIONAL INFORMATION
CONFLICT OF INTEREST
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call